JAK2 and essential thrombocythemia: In contrast to PMF or PV with myelofibrosis, these JAK2 V617F-negative HSC leukemias usually arise during the chronic phase of PV or ET, are often associated with a TP53 mutation and hydroxyurea therapy, and are extremely difficult to treat.